A very promising new study for Bucillamine for the treatment of COVID-19.

Shares :

5
(7)

Today Revive Therapeutics | RVV RVVTF had its biggest day in its history with more than 29 million shares traded and a 50% increase. During the day, the stock even had a more than 77% increase. The majority of companies linked to the psychedelics market have experienced strong growth today and companies like Mindmed (MMED) have even seriously approached the 2 billion market value.

But Revive Therapeutics is about to have the first results of its largest study, the FDA Phase 3 Clinical Trial for Bucillamine in COVID-19. The company estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020.

But on December 08, 2020, a study was published titled:

Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies.

http://revivethera.com/wp-content/uploads/2020/12/2020.12.08.415505v1.full_.pdf

In this study, they found that thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor, decrease the entry efficiency of SARS-CoV-2 spike pseudotyped virus, and inhibit SARS-CoV-2 live virus infection. Their findings uncover a vulnerability of SARS-CoV-2 to thiol-based drugs and provide rationale to test thiol-based drugs as novel treatments for COVID-19.

Bucillamine is among the 3 most effective and is therefore very promising for the result of the study to come in the coming weeks.

For more information visit the Revive Therapeutics website

Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 7

No votes so far! Be the first to rate this post.


Shares :